e-Drug3D

1476

SAXAGLIPTIN


INN
SAXAGLIPTIN

(has an active metabolite)

cas 361442-04-8
CLASS

ANTIDIABETIC
DIPEPTIDYL-PEPTIDASE IV INHIBITOR
HYPOGLYCEMIC AGENTS
TYPE 2 DIABETES MELLITUS
METABOLISM
METABOLITE OF SAXAGLIPTIN IS ONE-HALF AS POTENT AS SAXAGLIPTIN AS DPP4 INHIBITOR

ROUTE (list)

ORAL

ATC code

A10BD10
A10BD25
A10BH03
A10BD21

PK parameters

Cl 13.8 LITER / HOUR
PPB 0 PERCENT
t1/2 2.5 HOUR

Solubility

SPARINGLY SOLUBLE IN WATER


Target

TARGET DIPEPTIDYL PEPTIDASE-4 (DPP-4)

DrugCentral

Dipeptidyl peptidase 4 UNIPROT P27487 DPP4

Download SDF file (1R,3R,5R)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

Formula:
C18H25N3O2

Calculated chemical properties:

MW 315.41
NB_atoms 23
XLogP 1.16
PSA 79.67
NB_HD 3
NB_HA 5
fsp3 0.89
Lipinski(0=no;1=yes) 1

FDA
NDA 022350 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) ONGLYZA (ASTRAZENECA AB) APPROVAL= AP YEAR= 2009 NEWMOLECULARENTITY DISCONTINUED
NDA 200678 (pdf not found) INN (METFORMIN HYDROCHLORIDE ; SAXAGLIPTIN HYDROCHLORIDE) KOMBIGLYZE XR (ASTRAZENECA AB) APPROVAL= AP YEAR= 2010 DISCONTINUED
NDA 205942 (pdf not found) INN (SAXAGLIPTIN ; METFORMIN HYDROCHLORIDE) SAXAGLIPTIN;METFORMIN HYDROCHLORIDE (AMNEAL PHARMS) APPROVAL= TA YEAR= 2016
NDA 205959 (pdf not found) INN (SAXAGLIPTIN) SAXAGLIPTIN (PAR PHARM) APPROVAL= TA YEAR= 2016
NDA 209091 (pdf not found) INN (DAPAGLIFLOZIN ; SAXAGLIPTIN HYDROCHLORIDE) QTERN (ASTRAZENECA AB) APPROVAL= AP YEAR= 2017 DISCONTINUED
NDA 210874 (pdf not found) INN (DAPAGLIFLOZIN ; METFORMIN HYDROCHLORIDE ; SAXAGLIPTIN HYDROCHLORIDE) QTERNMET XR (ASTRAZENECA AB) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 211533 (pdf not found) INN (DAPAGLIFLOZIN ; SAXAGLIPTIN) DAPAGLIFLOZIN AND SAXAGLIPTIN (MSN LABS PVT LTD) APPROVAL= TA YEAR= 2020
NDA 205941 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN (AMNEAL) APPROVAL= AP YEAR= 2023 DISCONTINUED
NDA 205972 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN (AUROBINDO PHARMA) APPROVAL= AP YEAR= 2023
NDA 205980 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN (MYLAN) APPROVAL= AP YEAR= 2023
NDA 205994 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN (GLENMARK PHARMS LTD) APPROVAL= AP YEAR= 2023
NDA 205981 (pdf not found) INN (METFORMIN HYDROCHLORIDE ; SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE (MYLAN) APPROVAL= AP YEAR= 2023
NDA 206078 (pdf not found) INN (SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN (SUN PHARM) APPROVAL= AP YEAR= 2023 DISCONTINUED
NDA 206081 (pdf not found) INN (METFORMIN HYDROCHLORIDE ; SAXAGLIPTIN HYDROCHLORIDE) SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE (SUN PHARM) APPROVAL= AP YEAR= 2023
NDA 207678 (pdf not found) INN (METFORMIN HYDROCHLORIDE ; SAXAGLIPTIN HYDROCHLORIDE) METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE (DR REDDYS LABS SA) APPROVAL= AP YEAR= 2023
NDA 211532 (pdf not found) INN (DAPAGLIFLOZIN ; SAXAGLIPTIN MONOHYDRATE) DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (LUPIN LTD) APPROVAL= TA YEAR= 2024

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL